Min Liu

Min Liu

Auto-generated profile, based on publicly available information

Min Liu

H. Lee Moffitt Cancer Center & Research Institute 2 Proteomics and Metabolomics Core Tampa, Florida

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2022 in Cancer Research
Verified
Journal Article
Open access
PDF file
AEAsmaa El-Kenawi
Asmaa El-Kenawi
ABAnders Berglund
Anders Berglund
VEVeronica Estrella
Veronica Estrella
YZYonghong Zhang
Yonghong Zhang
MLMin Liu
Min Liu
RGRobert Gatenby
Robert Gatenby
Induction of cell death represents a primary goal of most anticancer treatments. Despite the efficacy of such approaches, a small population of “persisters” develop evasion strategies to therapy-induced cell death. While previous studies have identified mechanisms of resistance to apoptosis, the mechanisms by which persisters dampen other forms of cell death, such as pyroptosis, remain to be elucidated. Pyroptosis is a form of inflammatory cell death that involves formation of membrane pores, ion gradient imbalance, water inflow, and membrane rupture. Herein, we investigate mechanisms by which cancer persisters resist pyroptosis, survive, then proliferate in the presence of tyrosine kinase inhibitors (TKI). Lung, prostate, and esophageal cancer persister cells remaining after treatments exhibited several hallmarks indicative of pyroptosis resistance. The inflammatory attributes of persisters included chronic activation of inflammasome, STING, and type I interferons. Comprehensive metabolomic characterization uncovered that TKI-induced pyroptotic persisters display high methionine consumption and excessive taurine production. Elevated methionine flux or exogenous taurine preserved plasma membrane integrity via osmolyte-mediated effects. Increased dependency on methionine flux decreased the level of one carbon metabolism intermediate S-(5′-adenosyl)-L-homocysteine, a determinant of cell methylation capacity. The consequent increase in methylation potential induced DNA hypermethylation of genes regulating metal ion balance and intrinsic immune response. This enabled thwarting TKI resistance by using the hypomethylating agent decitabine. In summary, the evolution of resistance to pyroptosis can occur via a stepwise process of physical acclimation and epigenetic changes without existing or recurrent mutations. Significance: Methionine enables cancer cells to persist by evading pyroptotic osmotic lysis, which leads to genome-wide hypermethylation that allows persisters to gain proliferative advantages.

15 August 2022 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
RHRebecca S. Hesterberg
Rebecca S. Hesterberg
MLMin Liu
Min Liu
AEAya G. Elmarsafawi
Aya G. Elmarsafawi
JKJohn M. Koomen
John M. Koomen
EWEric A. Welsh
Eric A. Welsh
JCJohn L. Cleveland
John L. Cleveland
Chronic T-cell receptor (TCR) signaling in the tumor microenvironment is known to promote T-cell dysfunction. However, we reasoned that poorly immunogenic tumors may also compromise T cells by impairing their metabolism. To address this, we assessed temporal changes in T-cell metabolism, fate, and function in models of B-cell lymphoma driven by Myc, a promoter of energetics and repressor of immunogenicity. Increases in lymphoma burden most significantly impaired CD4+ T-cell function and promoted regulatory T cell (Treg) and Th1-cell differentiation. Metabolomic analyses revealed early reprogramming of CD4+ T-cell metabolism, reduced glucose uptake, and impaired mitochondrial function, which preceded changes in T-cell fate. In contrast, B-cell lymphoma metabolism remained robust during tumor progression. Finally, mitochondrial functions were impaired in CD4+ and CD8+ T cells in lymphoma-transplanted OT-II and OT-I transgenic mice, respectively. These findings support a model, whereby early, TCR-independent, metabolic interactions with developing lymphomas limits T cell–mediated immune surveillance.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
Disruption of GSH and glycolysis pathways enhances KRASG12C inhibitor efficacy. A, Scheme of mechanisms of action of BSO and glutor. B, Cell viability of H1792 (N = 3), H358 (N = 4), and HOP62 cells (N = 4) treated with BSO (500 μmol/L) or (C) glutor (50 nmol/L) alone or in combination with sotorasib (Soto; 10 μmol/L) or adagrasib (Adag; 1 μmol/L) for 96 hours. N = 3. Cell viability was measured using CellTiter-Glo luminescent cell viability assay. Data represent the mean ± SD (N = 3) and were analyzed by one-way ANOVA followed by Tukey post hoc test.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
GSTZ1 modulates the efficacy of KRASG12C inhibitors in KRASG12C-mutant NSCLC. A, Immunoblot analysis of GSTZ1 protein levels in noncancerous lung and KRASG12C-mutant NSCLC cell lines. B and C, Relative cell viability of H1792 and MRC-5 cells transfected with siNT or siGSTZ1 for 24 hours, followed by the treatment with sotorasib (Soto) or adagrasib (Adag) at indicated concentrations for additional 72 hours. N = 3. D, Crystal violet staining (left) and absorbance quantification (right) in H1792 cells with GSTZ1 overexpression (OE) or nontargeting control (NC) treated with Soto. GSTZ1 overexpression was confirmed by immunoblotting. N = 4. E, Viability of H1792 cells upon GSTZ1 knockout using two individual guide RNAs, sg-1and sg-2, with or without Soto treatment for 96 hours in 2D (N = 3). GSTZ1 protein levels were validated by immunoblotting. F, Cell viability of H1792 cells with NT and GSTZ1 knockout in 3D culture enabled using 96-well spheroid microplates. Soto (10 μmol/L) was incubated with spheroids for 72 hours after 48-hour spheroid formation. G, Representative brightfield images of 3D H1792 spheroids shown at scale bars of 400 μm. Cell viability was measured using 3D CellTiter-Glo luminescent cell viability assay. N = 3. Data represent the mean ± SD. Statistical significance was determined by one-way ANOVA with Tukey multiple comparisons test.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
GSTZ1 inhibition enhances AMPK phosphorylation and suppresses survival signaling. A, Immunoblots of H1792 lysates showing levels of phosphorylated and total AKT, ERK, AMPK, mTOR, and GSTZ1 following siGSTZ1, sotorasib (Soto; 1 μmol/L), and combined treatment for 96 hours. B, Quantification of phospho-protein signals relative to actin: p-AKT (S473, N = 5), p-ERK (T202/Y204, N = 3), p-mTOR (S2448, N = 4), and p-AMPK (T172, N = 4). Data represent the mean ± SD and were analyzed by one-way ANOVA with Tukey post hoc test.

11 June 2026
Verified
Other
Open access
YLYi Liao
Yi Liao
XLXueli Li
Xueli Li
MLMin Liu
Min Liu
VFVanessa C. Fernandes
Vanessa C. Fernandes
DDDerek Duckett
Derek Duckett
URUwe Rix
Uwe Rix
KRAS mutations are prevalent in lung cancer, but KRASG12C inhibitors exhibit limited efficacy, partly due to metabolic adaptations, such as enhanced glutathione (GSH) metabolism and increased glycolysis. Glutathione S-transferase zeta 1 (GSTZ1) is a metabolic enzyme that regulates cell metabolism; however, its role in KRAS-driven lung cancer remains underexplored. We recently reported that targeting GSTZ1 significantly enhances the efficacy of FDA-approved KRASG12C inhibitors in non–small cell lung cancer (NSCLC) cells. Untargeted metabolomics now revealed significant alterations in GSH and glycolytic pathways, marked by lowered lactate levels and increased oxidized GSH following GSTZ1 ablation. Moreover, pharmacologic inhibition of GSH synthesis and glucose uptake mimicked the sensitizing effects of GSTZ1 targeting. These metabolic shifts were accompanied by increased AMPK phosphorylation and reduced AKT phosphorylation, two key mediators of the response to KRASG12C inhibition. Our data reveal GSTZ1-associated metabolic and signaling alterations that contribute to drug resistance and identify GSTZ1 as a potential complementary target to sensitize KRAS-mutant NSCLC to KRAS-directed treatments.Significance:Targeting GSTZ1 sensitized KRASG12C-mutant NSCLC cells to KRASG12C inhibitors by disrupting glycolysis, GSH metabolism, and protein phosphorylation. GSTZ1 emerges as a mediator of drug resistance and a therapeutic target, supporting rational combination strategies that exploit metabolic vulnerabilities to enhance KRAS-targeted therapy efficacy and improve outcomes.